PURPOSE: Li-Fraumeni syndrome is a rare hereditary cancer syndrome associated with germline mutations in the TP53 gene. Although sarcomas, brain tumors, leukemias, breast and adrenal cortical carcinomas are typically recognized as Li-Fraumeni syndrome-associated tumors, the occurrence of gastrointestinal neoplasms has not been fully evaluated. In this analysis, we investigated the frequency and characteristics of gastric cancer in Li-Fraumeni syndrome. METHODS: Pedigrees and medical records of 62 TP53 mutation-positive families were retrospectively reviewed from the Dana-Farber/National Cancer Institute Li-Fraumeni syndrome registry. We identified subjects with gastric cancer documented either by pathology report or death certificate and performed pathology review of the available specimens. RESULTS: Among 62 TP53 mutation-positive families, there were 429 cancer-affected individuals. Gastric cancer was the diagnosis in the lineages of 21 (4.9%) subjects from 14 families (22.6%). The mean and median ages at gastric cancer diagnosis were 43 and 36 years, respectively (range: 24-74 years), significantly younger compared with the median age at diagnosis in the general population based on Surveillance Epidemiology and End Results data (71 years). Five (8.1%) families reported two or more cases of gastric cancer, and six (9.7%) families had cases of both colorectal and gastric cancers. No association was seen between phenotype and type/location of the TP53 mutations. Pathology review of the available tumors revealed both intestinal and diffuse histologies. CONCLUSIONS: Early-onset gastric cancer seems to be a component of Li-Fraumeni syndrome, suggesting the need for early and regular endoscopic screening in individuals with germline TP53 mutations, particularly among those with a family history of gastric cancer.
PURPOSE: Li-Fraumeni syndrome is a rare hereditary cancer syndrome associated with germline mutations in the TP53 gene. Although sarcomas, brain tumors, leukemias, breast and adrenal cortical carcinomas are typically recognized as Li-Fraumeni syndrome-associated tumors, the occurrence of gastrointestinal neoplasms has not been fully evaluated. In this analysis, we investigated the frequency and characteristics of gastric cancer in Li-Fraumeni syndrome. METHODS: Pedigrees and medical records of 62 TP53 mutation-positive families were retrospectively reviewed from the Dana-Farber/National Cancer Institute Li-Fraumeni syndrome registry. We identified subjects with gastric cancer documented either by pathology report or death certificate and performed pathology review of the available specimens. RESULTS: Among 62 TP53 mutation-positive families, there were 429 cancer-affected individuals. Gastric cancer was the diagnosis in the lineages of 21 (4.9%) subjects from 14 families (22.6%). The mean and median ages at gastric cancer diagnosis were 43 and 36 years, respectively (range: 24-74 years), significantly younger compared with the median age at diagnosis in the general population based on Surveillance Epidemiology and End Results data (71 years). Five (8.1%) families reported two or more cases of gastric cancer, and six (9.7%) families had cases of both colorectal and gastric cancers. No association was seen between phenotype and type/location of the TP53 mutations. Pathology review of the available tumors revealed both intestinal and diffuse histologies. CONCLUSIONS: Early-onset gastric cancer seems to be a component of Li-Fraumeni syndrome, suggesting the need for early and regular endoscopic screening in individuals with germline TP53 mutations, particularly among those with a family history of gastric cancer.
Authors: Carla Oliveira; Maria Cristina Bordin; Nicola Grehan; David Huntsman; Gianpaolo Suriano; José Carlos Machado; Tuula Kiviluoto; Lauri Aaltonen; Charles E Jackson; Raquel Seruca; Carlos Caldas Journal: Hum Mutat Date: 2002-05 Impact factor: 4.878
Authors: G Keller; H Vogelsang; I Becker; S Plaschke; K Ott; G Suriano; A R Mateus; R Seruca; K Biedermann; D Huntsman; C Döring; E Holinski-Feder; A Neutzling; J R Siewert; H Höfler Journal: J Med Genet Date: 2004-06 Impact factor: 6.318
Authors: S A Gayther; K L Gorringe; S J Ramus; D Huntsman; F Roviello; N Grehan; J C Machado; E Pinto; R Seruca; K Halling; P MacLeod; S M Powell; C E Jackson; B A Ponder; C Caldas Journal: Cancer Res Date: 1998-09-15 Impact factor: 12.701
Authors: A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun Journal: Br J Cancer Date: 2000-06 Impact factor: 7.640
Authors: Debra L Friedman; Nina S Kadan-Lottick; John Whitton; Ann C Mertens; Yutaka Yasui; Yan Liu; Anna T Meadows; Leslie L Robison; Louise C Strong Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-08 Impact factor: 4.090
Authors: Irma Kluijt; Rolf H Sijmons; Nicoline Hoogerbrugge; John T Plukker; Daphne de Jong; J Han van Krieken; Richard van Hillegersberg; Marjolijn Ligtenberg; Eveline Bleiker; Anemieke Cats Journal: Fam Cancer Date: 2012-09 Impact factor: 2.375
Authors: Namrata Setia; Jeffrey W Clark; Dan G Duda; Theodore S Hong; Eunice L Kwak; John T Mullen; Gregory Y Lauwers Journal: Oncologist Date: 2015-09-30
Authors: Vivian Y Chang; Noah Federman; Julian Martinez-Agosto; Sergei F Tatishchev; Stanley F Nelson Journal: Pediatr Blood Cancer Date: 2012-09-26 Impact factor: 3.167
Authors: Małgorzata Skierucha; Anya Na Milne; G Johan A Offerhaus; Wojciech P Polkowski; Ryszard Maciejewski; Robert Sitarz Journal: World J Gastroenterol Date: 2016-02-28 Impact factor: 5.742